A detailed history of Truist Financial Corp transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Truist Financial Corp holds 54,583 shares of ACAD stock, worth $931,731. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,583
Previous 50,006 9.15%
Holding current value
$931,731
Previous $812,000 3.45%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$15.14 - $19.14 $69,295 - $87,603
4,577 Added 9.15%
54,583 $840,000
Q2 2024

Aug 20, 2024

BUY
$14.62 - $18.42 $100,687 - $126,858
6,887 Added 15.97%
50,006 $812,000
Q1 2024

May 10, 2024

SELL
$17.79 - $30.86 $370,156 - $642,104
-20,807 Reduced 32.55%
43,119 $797,000
Q4 2023

Feb 02, 2024

SELL
$20.78 - $31.77 $682,082 - $1.04 Million
-32,824 Reduced 33.93%
63,926 $2 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $668,297 - $1.07 Million
32,068 Added 49.58%
96,750 $2.02 Million
Q2 2023

Aug 01, 2023

BUY
$17.8 - $25.65 $362,354 - $522,157
20,357 Added 45.93%
64,682 $1.55 Million
Q1 2023

May 05, 2023

BUY
$16.32 - $20.92 $106,716 - $136,795
6,539 Added 17.31%
44,325 $834,000
Q4 2022

Feb 17, 2023

SELL
$14.2 - $18.63 $57,964 - $76,047
-4,082 Reduced 9.75%
37,786 $601,000
Q3 2022

Oct 26, 2022

SELL
$14.11 - $18.27 $106,008 - $137,262
-7,513 Reduced 15.21%
41,868 $685,000
Q2 2022

Jul 22, 2022

SELL
$13.01 - $27.22 $156,328 - $327,075
-12,016 Reduced 19.57%
49,381 $696,000
Q1 2022

Apr 22, 2022

SELL
$20.94 - $27.5 $436,829 - $573,677
-20,861 Reduced 25.36%
61,397 $1.49 Million
Q4 2021

Feb 14, 2022

SELL
$16.79 - $27.09 $365,048 - $588,990
-21,742 Reduced 20.91%
82,258 $1.92 Million
Q3 2021

Nov 05, 2021

BUY
$15.78 - $24.77 $267,833 - $420,421
16,973 Added 19.5%
104,000 $1.73 Million
Q2 2021

Aug 16, 2021

BUY
$19.4 - $27.42 $220,965 - $312,313
11,390 Added 15.06%
87,027 $2.12 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $823,433 - $1.81 Million
32,911 Added 77.03%
75,637 $1.95 Million
Q4 2020

Nov 19, 2021

SELL
$41.04 - $56.79 $164,077 - $227,046
-3,998 Reduced 8.56%
42,726 $2.28 Million
Q4 2020

Feb 18, 2021

BUY
$41.04 - $56.79 $712,290 - $985,647
17,356 Added 59.1%
46,724 $2.5 Million
Q3 2020

Nov 13, 2020

BUY
$36.42 - $57.0 $473,532 - $741,114
13,002 Added 79.45%
29,368 $1.21 Million
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $80,640 - $108,307
2,054 Added 14.35%
16,366 $793,000
Q1 2020

May 15, 2020

BUY
$31.65 - $46.87 $38,328 - $56,759
1,211 Added 9.24%
14,312 $605,000
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $474,387 - $673,391
13,101 New
13,101 $561,000
Q4 2017

Jan 29, 2018

SELL
$26.84 - $39.14 $156,638 - $228,421
-5,836 Closed
0 $0
Q3 2017

Oct 23, 2017

BUY
$29.49 - $38.37 $172,103 - $223,927
5,836
5,836 $220,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Truist Financial Corp Portfolio

Follow Truist Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.